The Perioperative Pivot: Navigating the New Frontier for Immunotherapy in Early Stage Cancers

Immune checkpoint inhibitors (PD 1/PD L1) are moving into perioperative (neoadjuvant/adjuvant) care for early-stage solid tumours. This shift is an opportunity - and a strategic black box.

In this Point of View, Ipsos’ experts decode the new perioperative landscape and offer a practical plan for clinical and commercial impact. Grounded in our therapy area experience and a new Ipsos survey of US based medical oncologists, the paper addresses three pressing questions:

• How to align on a consistent definition of “high-risk” patients across the multidisciplinary care team.
• How to translate event-free and disease-free survival into clear value stories for stakeholders beyond medical oncology.
• How to fix handoff gaps between diagnosis, surgery, and systemic treatment so eligible patients stay on pathway.

Read to look ahead and delve into the perioperative pivot for immuno-oncology.